Anrotinib
PreclinicalSmall molecule
Anrotinib is one of 77 small molecule programs targeting Adenocarcinoma. It is currently in Preclinical.
2
Indications
2
Total Trials
0
Active Trials
76
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
337 competitors in Adenocarcinoma
#DrugCompanyPhaseTrials
1Gemzar
Johnson & JohnsonPhase 3
Xeloda
EEngelhard Arzneimittel GmbH & Co.KG
Phase 3
Taxol
TevaPhase 3
Taxotere
AAvyxa
Phase 3
Opdivo
Bristol-Myers SquibbPhase 3
Paraplatin
AAvyxa
Phase 3
Adrucil
EElorac, Inc.
Phase 3
Camptosar
EEastern Cooperative Oncology Group
Phase 3
Rilvegostomig
AstraZenecaPhase 3
Rilotumumab
AmgenPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Anrotinib. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- HHenan Cancer Hospital